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The expression of mRNA for retinoic acid receptor beta (RAR-8) was induced by all trans-retinoic acid in murine S91 melanoma cells. The induction 
of RAR-/I was dose-dependent, rapid and insensitive to cycloheximide. Both 13-cis-retinoic acid and 3,Cdidehydro-aN trans-retinoic acid also in- 
duced expression of RAR-jI but were only effective at concentrations lOO-fold greater than all trans-retinoic acid. The expression of RAR-a and 
RAR-), was unaffected by retinoic acid. 
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1. INTRODUCTION 
The biological effects of retinoic acid and its 
derivatives are likely to be mediated, at least in part, by 
retinoic acid receptors (RAR), a class of nuclear 
retinoic acid binding proteins [1,2] closely related to 
steroid and thyroid hormone receptors [3-61. Three 
types of RAR, RAR-(Y, RAR-P and RARy, have so far 
been identified in rodents and humans and are highly 
conserved between species [7]. At least two transcripts 
for each type of RAR can be identified by Northern 
blotting [8,9] and in the case of RAR--, the two major 
transcripts represent alternatively spliced products dif- 
fering in sequence at the amino terminus of the 
predicted protein [9]. Patterns of expression of RAR 
transcripts differ markedly between tissues [8,10] and 
the diversity of biological effects of retinoic acid is thus 
presumably mediated by different patterns of RAR- 
gene expression and different splicing patterns in dif- 
ferent tissues and cell types. 
Retinoic acid inhibits the proliferation of many cell 
types in vitro and this may be accompanied by the ex- 
pression of different cell phenotypes and differentiation 
markers, such as in the case of some teratocarcinoma 
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and melanoma lines [11,12]. For example, S91 murine 
melanoma cells respond to retinoic acid by a reduction 
in proliferation and an increase in pigmentation [12]. 
Here, we show that retinoic acid also induces RAR ex- 
pression in murine S91 melanoma cells and, using this 
response as a bioassay, we have compared the 
biological potency of retinoic acid with its 13-cis isomer 
and the 3,4-didehydro derivative. 
2. MATERIALS AND METHODS 
2.1. Cell culWre 
S91 melanoma cells (strain M3) were from Flow Laboratories, Ir- 
vine, Scotland, and were cultured in an atmosphere of 5% CO2 in air 
at 37°C in Dulbecco’s minimal essential medium (DMEM), contain- 
ing 10% foetal calf serum (FCS). Cells were seeded at a density of 1.1 
x lo5 cells per cm2 growth area in either 75 or 25 cm2 tissue culture 
flasks; solutions of all rrans-retinoic acid (Sigma), 13-cis-retinoic acid 
(Roche Products, Wdwyn Garden City, Herts) or 3,4-didehydro-aN 
truns-retinoic acid (Hoffmann-La Roche, Basel) in ethanol were add- 
ed to final concentrations within the range 0.1-1000 nM after allow- 
ing the cells to attach overnight. An equal volume (< 5 ~1 per 20 ml 
medium) of ethanol was added to control cultures. Concentrations of 
the stock solutions for all 3 retinoids were estimated using an extinc- 
tion coefficient of 36,500 at 343 nm. Cycloheximide was used at a 
concentration of 10 pggrnl-‘. Actinomycin D was dissolved in 
methanol and added to a final concentration of 5 pg.rnl- ‘. 
For experiments with CAMP, dibutyryl CAMP was dissolved in 
DMEM and added to cells to a final concentration of 1 mM; 
isobutylmethylxanthine (IBMX) was dissolved in 1 M NaOH at 100 
mM and added to cells to give a final concentration of 1 mM; OL- 
melanocyte stimulating hormone (a-MSH) was dissolved in DMEM 
and added to cells to a final concentration of 0.1 pM. 
2.2. RNA extractions and Northern blotting 
In some initial experiments, total cellular RNA was prepared by the 
guanidinium isothiocyanate/caesium chloride method [ 131. Other- 
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wise, total cytoplasmic RNA was prepared by the ‘miniprep’ method 
of Wilkinson [14]. RNA (30 gg per track for 1 cm wide slots) was size- 
fractionated on t .2% agarose/formaldehyde gels and transferred by 
vacuum blotting with 1.8 M NaCl, 0.01 M EDTA, 0.1 M sodium 
phosphate, pH 7.4, (10 x SSPE) to nylon membranes (Schleicher and 
Schuell). Membranes were hybridised [15] at 42°C with “P-1abelled 
probe using 50% formamide, 6 x SSPE, 0.2% w/v Ficoll400, 0.2% 
w/v polyvinylpyrrolidone, 0.2% bovine serum albumin (fraction V), 
0.5% SDS, 5% Dextran Sulphate and 100 pg/ml single-stranded car- 
rier DNA [16] as the prehybridization and hybridization buffer. After 
hybridisation, membranes were washed 3-4 times in 1 x SSPE, 0. I % 
SDS for > 15 min each at 68°C and exposed to X-ray film with inten- 
sifyjng screens at - 70°C. For quantitative autoradiography, X-ray 
film was preflashed [lS] and the autoradio~aphs canned using an 
LKB laser scanning densitometer. 
2.3. Probes 
The RAR-ol probe was a K~II/SQCI fragment (503 bp) from the 5’ 
end of the human RAR-(Y cDNA (31. The human RAR-0 probe con- 
sisted of the complete cDNA insert (1400 bp) of the plasmid pCOD20 
[5]. The human RAR-y probe was the full length cDNA insert (1500 
bp) [7]. To control for RNA loading, membranes were reprobed with 
a rat @actin probe consisting of a 1200 bp BgZl fragment of the 
pRBA-1 cDNA clone isolated by P. Gunning. Probes were labelled 
with [32P]dCTP (Amersham international, 3000 Ci.mmol- ‘) to a 
specific activity of approximately 10’ dprnepg- ’ [17]. The human 
RAR-rr and RAR-y cDNA probes were provided by Martin Petkovich 
and Pierre Chambon, Strasbourg, France and the RAR-6 probe by 
Anne Dejean, Paris, France. 
3. RESULTS 
3.1. Expression of mRNA for RAR-a, RAR-/3 and 
RAR-y in S91 melanoma cells 
We have previously reported [2] that RAR-a! and 
RAR-P mRNA are present in poly-(A) + RNA from S91 
cells, although the signal intensity for RAR-a was very 
low by comparison with some other cell lines. In subse- 
quent studies on S91 cells using tota cytoplasmic RNA, 
2.8 and 3.6 kb BAR-a: transcripts and a single 3.4 kb 
RAR-8 transcript were clearly detectable (Fig. 1) The 
RAR--, probe detects transcripts approximately 3.3 kb 
in size in human [7] and rat tissues (Rees and Redfern, 
unpublished results); in S91 melanoma cells, the RAR-7 
probe detected transcripts of a similar size, but these 
were expressed at a low level compared to RAR-cu and 
RAR-@. When S91 cells were treated with all trans- 
retinoic acid, there was a marked stimulation of expres- 
sion of RAR-fi (Fig. 1). A similar induction of RAR-0 
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Fig. 1. Northern blot of total cytoplasmic RNA from S91 cells treated 
with lo- 6 M retinoic acid (lanes 2, 5 and 7:‘ + ‘) or ethanol as control 
(lanes 1, 3, 4 and 6: ‘ - ‘) and probed with RAR-o (lanes 1,2 and 3), 
RAR-@ (lanes 4 and 5) and RAR-y (lanes 6 and 7). 
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Fig. 2. Time course (hours) of induction of RAR-8 in response to 
10 - ’ M retinoic acid. (A) Northern blot of RNA probed for RAR-fl 
(top panel) and p-actin (bottom panel). (B) Induction of RAR-fl with 
time as a proportion of zero-time control, corrected for @-actin signal 
intensity. 
in response to retinoic acid was also observed in the B16 
Fl and FIO murine melanoma sublines (data not 
shown). Although there was also an apparent induction 
of a novel RAR-a transcript running just ahead of the 
3.6 kb RAR-a, transcript (Fig. l), this coincides in posi- 
tion with the RAR-P transcript, was not detectable in 
blots washed at higher stringency and may therefore be 
due to cross hybridisation of the RAR-a! probe with 
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Fig. 3. Induction of RAR-/3 after treating S91 cells for 8 h with 
retinoic acid (10 - 6 M) in the presence of absence or cycloheximide (10 
pg - ml -I). Northern blot probed for RAR-& Lane 1, control; lane 
2, retinoic acid (10e6 M); lane 3, cycloheximide alone; lane 4, 
cycloheximide and retinoic acid; lane 5, retinoic acid and actinomycin 
D. 
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Fig. 4. Induction of RAR-@ in response to lo-’ M retinoic acid in the 
presence of dibutyryl CAMP, IBMX (phosphodiesterase inhibitor) 
and (u-MSH. Northern blot probed for RAR-8. Lane 1, control; lane 
2, retinoic acid alone; lane 3, dibutyryl CAMP alone; lane 4, retinoic 
acid and dibutyryl CAMP; lane 4, IBMX alone; lane 6, retinoic acid 
and IBMX; lane ‘7, retinoic acid and IBMX in the presence of a-MSH. 
RAR-/3 transcripts. There was no evidence for induc- 
tion of RAR-7 in response to retinoic acid (Fig. 1). 
3.2. Induction of expression of RAR-/3 is rapid and retinoic acid (0, n = 4). 3,4didehydroretinoic acid ( o , n = 2). 
independent of protein synthesis 
The induction of RAR-/3 in S91 cells is a rapid 
response to retinoic acid and was detectable within l-2 
h of addition of a& trans-retinoic acid, producing a 
6-7-fold increase in RAR-B expression by 24 h (Fig. 2). 
This response was not in~bited by cyclohe~mide (Fig. 
3). However, the presence of cyclohe~~de did induce 
a low level of expression of a smaller RAR-fi transcript. 
In the presence of actinomycin D, the induction of 
RAR-fl in response to retinoic acid was completely 
abolished (Fig. 3). 
treatments known to produce a 4-8-fold increase in in- 
tracellular CAMP levels in S91 cells [19], had no detec- 
table effect on the induction of RAR-P by retinoic acid 
(Fig. 4). 
3.3. lose-dependent induetion of RAR-0 by all trans- 
retinoic acid, 13-cis-retinoic acid and 3,4-dide- 
hydro-all trans-retinoic acid 
The induction of RAR-/3 was dose-dependent (Fig. 
RAR-/3 is reportedly induced by retinoic acid in F9 
embryonal carcinoma cells and this effect is inhibited 
by culturing the cells with the CAMP analogue, 
dibutyryl CAMP [ 181. However, in S91 cells, incubation 
with dibutyryl CAMP or the phosphodiesterase in- 
hibitor IBMX in the presence and absence of oMSH, 
5), detectable with 0.1 nM ail trans-retinoic acid, and 
gave a response 50% of maximal within the concentra- 
tion range 0.1-l nM (Fig. 6). The 13-cis isomer of 
retinoic acid was much less effective, inducing a detec- 
table response at a concentration of 10 nM with a 
response 50% of maximal within the range 10-100 nM. 
The 3,4-didehydro derivative, recently reported to be 
6-fold more abundant than a/l trunk-retinoic acid in 
chick limb buds [ZO], only detectably induced RAR-8 
expression at concentrations above 10 nM and gave a 
poorer response than 13-cis-retinoic acid (Fig. 6). 
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Fig. 5. Dose-dependence of the induction of RAR-@ in response to in- 
cubation for 6 h with 0.1 nM, 1 nM, 10 nM, 100 nM UN trum-retinoic 
acid (panel a), 13-cis-retinoic acid (panel b) and 3,Cdidehydroretinoic 
acid (panel c). Control (no retinoic acid) = 0. Northern blot probed 
for RAR-8. 
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Fig. 6. Dose-dependence of RAR-@ induction expressed as a propor- 
tion of the untreated control and corrected for the @-actin signal in- 
tensity. Error bars: f SE. all tram-retinoic acid (0, n = 3), 13-cl- 
4. DISCUSSION 
S91 melanoma cells are clearly similar to human 
hepatocarcinoma cells with respect o the retinoic acid- 
mediated induction of RAR-@ [21]. The rapidity of the 
response and insensitivity to cycloheximide suggests 
that, as in hepatocarcinoma cells [21], the induction of 
RAR-@ is a direct tr~scription~ effect. A retinoic acid- 
mediated induction of RAR-/3 has also been observed in 
F9 teratocarcinoma cells but in this cell type the 
response may be less rapid than in either S91 or 
hepatocarcinoma cells and, unlike S91 cells, is inhibited 
by CAMP [ 181. The retinoic acid-mediated induction of 
RAR-/3 shows considerable cell type specificity and also 
occurs in normal dermal fibroblasts but not in HL60 
promyelocytic leukaemia cells or normal human 
keratinocytes (Daly and Redfern, unpublished data). 
21 
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Although a retinoic acid response element (RARE) has 
been identified at the 5 ’ end of the RAR-P gene [22], it 
is clear that other factors also regulate the expression of 
RAR-P. Both RAR-(w and RAR-/3 are expressed at a low 
level in unstimulated S91 cells and it is not yet clear 
whether the retinoic acid-mediated induction of RAR-/3 
represents a positive autoregulatory loop, or is 
mediated by RAR-a, RAR-y or by an as yet unknown 
mechanism. 
The dose response studies reported here are in agree- 
ment with KD estimates of 10 - lo to lo- 9 M for RAR-P 
[5]. The 13-cis isomer is much less effective than ail 
trans-retinoic acid in inducing expression of RAR-P. In 
addition to nuclear retinoic acid receptors, a low 
molecular weight, cytosolic retinoic acid binding pro- 
tein (CRABP) is present in many retinoic acid respon- 
sive cell lines and could act as a shuttle protein deliver- 
ing retinoic acid to nuclear receptors (for review see 
[23]). Since 13-cis-retinoic acid has a 25fold lower af- 
finity for CRABP than does afi trans-retinoic acid [24] 
the existence of such a system could result in a poor 
response to 13-cis-retinoic acid. However, the role of 
CRABP is not known and in S91 (clone M3) cells 
CRABP has been reported to be below detectable limits 
[25], although we have found low levels of CRABP in 
S91 cells (Daly and Redfern, unpublished data). In F9 
cells, where CRABP is present at a level comparable to 
S91 cells (Daly and Redfern, unpublished data), it has 
been shown that there is a good correlation between the 
biological potency of retinoids and affinity for nuclear 
retinoic acid receptors [26]; it is thus likely that the dif- 
ferential response of S91 cells to the two retinoic acid 
isomers reflects a true difference in their respective af- 
finities for RARs. 
3,4_didehydroretinoic acid has recently been iden- 
tified in chick limb buds where it is present at concen- 
trations 6-fold higher than all trans-retinoic acid and is 
reportedly equipotent with all trans-retinoic acid in 
disrupting normal morphogenesis [20]. However, in 
S91 cells this retinoid has a much lower activity than all 
trans-retinoic acid in inducing expression of RAR-0. If 
this response is indeed RAR-mediated, the high degree 
of similarity of the ligand binding regions between the 
different RAR types [7] argues that 3,4-didehydro- 
retinoic acid itself may not be an important RAR ligand 
in vivo. Nevertheless, a distinct class of retinoid recep- 
tor, designated RXR, has recently been described [27]. 
Although retinoic acid can activate RXR, the high con- 
centrations of retinoic acid required [27] suggest hat it 
is not the true ligand. It is thus possible that a distinct 
class of retinoid receptor, such as RXR, may exist for 
which 3,Cdidehydroretinoic acid is the natural ligand. 
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